Juan Luis
Gómez Sirvent
Researcher in the period 1992-2022
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublications in collaboration with researchers from Hospital Universitari de Bellvitge (18)
2023
-
Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021
Journal of Medical Virology, Vol. 95, Núm. 12
2021
2020
-
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300
2019
-
Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain
Open Forum Infectious Diseases, Vol. 6, Núm. 2
-
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700
2017
-
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088
-
HIV type 2 epidemic in Spain: Challenges and missing opportunities
AIDS, Vol. 31, Núm. 10, pp. 1353-1364
-
Human T-lymphotropic virus type 1 infection and disease in Spain
AIDS, Vol. 31, Núm. 12, pp. 1653-1663
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
2016
-
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study
International Journal of Infectious Diseases, Vol. 53, pp. 46-51
2014
-
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 9
-
HIV-2 and HTLV-1 infections in Spain, a non-endemic region
AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159
-
HIV-2 viral tropism influences CD4+ T cell count regardless of viral load
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194
2010
-
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study
The Lancet, Vol. 376, Núm. 9738, pp. 340-345
2009
-
Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality
Current HIV Research, Vol. 7, Núm. 2, pp. 224-230
2000
-
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish Earth-2 Study
Journal of Acquired Immune Deficiency Syndromes, Vol. 25, Núm. 1, pp. 26-35
-
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: The Scan Study
AIDS, Vol. 14, Núm. 16, pp. 2485-2494